 |
Faster development of API and Formulations with improved capability to screen polymorphs through digital platforms |
|
Deeper understanding of our product in relation to the reference product to develop
a strong scientific rationale for regulatory authorities |
|
Stronger rationales for waivers to bypass expensive clinical studies supported by
data which can only be obtained through advanced characterisation |
|
Higher role in the development of proprietary products |
|
Better support to our manufacturing plants in addressing queries from customers
and authorities |
|
Further support in characterisation capabilities for functions like packaging |
|
|
Accelerated discovery of novel polymorphs which will
translate
to huge benefits for our API
business |
|
The histogram shows an approximate 75% saving in
man-hours for 96 slurry
experiments |
|
This addition of state-of-the-art system has increased
productivity of polymorph
screening in Dr. Reddy's by
300-400% |
|
